Morpheus8V is a specialized radiofrequency (RF) microneedling treatment designed for women’s intimate wellness. At FEM Women’s Wellness, we use Morpheus8V to restore vaginal and vulvar tissue health, improve laxity, and support function with minimal downtime. This treatment is especially effective for women experiencing changes after childbirth, aging, or menopause, helping restore long-lasting tissue health and confidence.
Morpheus8V at FEM Women’s Wellness
Advanced RF Microneedling for intimate wellness, tightening, and tissue remodeling
Morpheus8V is a specialized radiofrequency (RF) microneedling treatment designed for women’s intimate wellness. At FEM Women’s Wellness, we use Morpheus8V to restore vaginal and vulvar tissue health, improve laxity, and support function with minimal downtime.
What is Morpheus8V?
Morpheus8V is part of the Empower RF platform, specifically engineered for women’s health. It delivers fractional RF energy through microneedling directly to the vaginal canal and external vulvar tissues. This combination stimulates collagen and elastin, remodels connective tissue, and enhances local circulation — supporting both cosmetic and functional improvements.
The result: stronger, tighter, more resilient tissue that can improve comfort, confidence, and quality of life.
Morpheus8V is FDA-cleared for women’s health indications and clinical studies support the safety and efficacy of fractional RF microneedling in gynecologic applications.
How it works?
A comfortable, sterile handpiece delivers fine microneedles and RF energy to the tissue .
Controlled thermal stimulation triggers natural healing and new collagen formation.
Over the following weeks, tissues remodel and strengthen, leading to improvements in structure and function.
There is minimal downtime post-procedure, with most patients being able to resume normal activity after 48 hours (including intimacy). Most patients notice improvements of symptoms within 4-8 weeks, while full benefits continue to develop for 3–6+ months after treatment.
Who can benefit?
Morpheus8V is an excellent non‑surgical option for women experiencing:
- Vaginal or vulvar laxity (often after childbirth, aging, or hormonal changes)
- Vaginal dryness or discomfort with intimacy
- Decreased sensitivity or sexual satisfaction
- Tissue changes related to perimenopause or menopause
- Cosmetic concerns about vulvar appearance
Morpheus8V is safe for many women, but a consultation with Northern Nevada’s first and only Morpheus V specialist will determine if you’re a good candidate.
Why choose FEM Women’s Wellness for Morpheus8V?
FEM Women’s Wellness is a specialized women’s health clinic that provides the Northern Nevada community with one of the few FDA-cleared non-surgical options to enhance women’s health. We are proud to lead the way in women’s health solutions as Northern Nevada’s first and only gynecological provider to offer this non-hormonal option to treat common gynecologic symptoms.
We offer personalized care plans tailored to your anatomy, health history, and goals, as well as a discreet, compassionate environment where women can feel comfortable discussing sensitive concerns.
Ready to learn more or book a consultation?
Schedule a confidential, individualized consultation to explore if Morpheus8V is right for you.
Call: (775) 993-9292
Location: FEM Women’s Wellness
Safety & Side Effects
Morpheus8V is FDA-cleared for women’s health indications and has been shown to be safe when performed by trained providers. Temporary redness, swelling, sensitivity, or mild spotting are the most common effects and typically resolve within a few days.
Published data support the safety profile and efficacy of fractional RF for vaginal applications:
- Kamilos MF, et al. Lasers Surg Med. 2017 — showed improvements in vaginal laxity with minimal side effects.
- Samuels JB, et al. J Drugs Dermatol. 2019 — fractional RF for vulvovaginal rejuvenation demonstrated safety and patient satisfaction.
- Cassuto D, et al. Lasers Surg Med. 2021 — reported enhanced vaginal laxity and sexual function scores with fractional RF.
- Tadir Y, et al. Climacteric. 2020 — review supports energy-based therapies including RF for genitourinary syndrome of menopause (GSM).
- Salvatore S, et al. Int Urogynecol J. 2021 — demonstrated improvements in vaginal health index and patient satisfaction after fractional RF treatments.
This page is intended for educational purposes and does not replace individualized medical advice. Your provider will review your full medical history and expectations during consultation